Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) fell 7.6% during mid-day trading on Thursday . The stock traded as low as $2.14 and last traded at $2.19, with a volume of 145,639 shares. The stock had previously closed at $2.37.

Several research analysts recently weighed in on the company. Roth Capital assumed coverage on Conatus Pharmaceuticals in a research report on Friday, July 1st. They issued a “buy” rating on the stock. Brean Capital reaffirmed a “buy” rating and issued a $7.00 target price (down from $13.00) on shares of Conatus Pharmaceuticals in a research report on Monday, May 9th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Monday, April 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $9.66.

The company’s 50-day moving average is $2.18 and its 200-day moving average is $2.20. The company’s market cap is $45.10 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.08. During the same period in the prior year, the firm posted ($0.31) earnings per share. On average, equities research analysts anticipate that Conatus Pharmaceuticals Inc. will post ($1.40) EPS for the current fiscal year.

A hedge fund recently raised its stake in Conatus Pharmaceuticals stock. Jennison Associates increased its stake in shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned approximately 3.32% of Conatus Pharmaceuticals worth $2,933,000 at the end of the most recent reporting period.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.